Clinical Cases in Pharmacology Clinical Cases  ·  Psychiatry IV  ·  Substance-Related Disorders  ·  Benzodiazepine Selection in Hepatic Impairment
Psychiatry IV, Case SubstanceRelated-0004 — Substance-Related Disorders

Benzodiazepine Selection for Alcohol Withdrawal in Hepatic Impairment

Two patients in alcohol withdrawal share the same syndrome and nearly the same CIWA score. Only one of them has a liver that can safely clear the usual first-choice drug.

Abbreviations, terms, and other agents mentioned in this case CIWA-Ar — Clinical Institute Withdrawal Assessment for Alcohol, revised  ·  Child-Pugh — a staging system for how well a cirrhotic liver is still functioning  ·  phase 1 / phase 2 metabolism — oxidative (phase 1) vs. conjugative/glucuronidation (phase 2) hepatic drug clearance pathways  ·  hepatic encephalopathy — confusion caused by the liver’s reduced ability to clear ammonia and other toxins
Presentation
Case A

J.K. had a witnessed tonic-clonic seizure at home this morning, and by the time EMS reached the emergency department he was tremulous, diaphoretic, with a heart rate in the 110s. He is twenty-nine. His mother, who found him, says he'd complained of feeling “shaky and wired” the evening before, but nothing like a seizure had happened during any of his previous attempts to cut back over the years. This is his first known withdrawal seizure, and it arrived at the worst possible moment on his own calendar.

He got a conditional job offer two weeks ago for a maintenance role at a regional logistics company — one that pays enough to finally move out of his parents' house — contingent on a clean drug and alcohol screen at his start date in ten days. His drinking has been heavy on weekends for about three years, roughly twelve to fifteen drinks over a Friday-through-Sunday stretch with lighter drinking on weekdays, but he had never had a documented withdrawal episode before. Six days before the screening date he stopped abruptly, reasoning he had plenty of time to “get it out of his system.” His labs are otherwise unremarkable — normal liver enzymes, normal renal function, a mildly low magnesium at 1.5 mg/dL, and a head CT read as unremarkable given the new-onset seizure. He has no other medical history: no liver disease, no seizure history, no psychiatric diagnosis. What he is anxious about now, openly and repeatedly, is how long inpatient management will take against the calendar he's working against — he has already called his prospective employer once from the emergency department to ask, without explaining why, whether the start date has any flexibility at all.

Patient A · J.K. Index Case
History
Heavy weekend drinking × 3 years; first witnessed withdrawal seizure this admission
Liver function
AST 22, ALT 19, normal synthetic function
CIWA-Ar on arrival
19 (tremor, diaphoresis, tachycardia, one witnessed seizure)
Electrolytes
Mg²⁺ 1.5 mg/dL, otherwise normal
Context
Job start date in 10 days, contingent on clean screening

Case A — front-load or titrate against the clock

Hospitalist Opening

Front-load him with diazepam. His liver is completely normal, so the drug's long half-life and active metabolites aren't a liability here, they're the mechanism — the drug tapers itself as levels fall, which is exactly the forgiving margin I want in someone who's already had one withdrawal seizure this admission.

Emergency Medicine Physician Response

I'd rather manage him on symptom-triggered CIWA-Ar reassessment. Saitz's randomized trial found symptom-triggered dosing meant significantly less total benzodiazepine and a shorter course than fixed dosing, in patients very much like him — and he has a real, stated reason to care about getting through this efficiently, not just safely.

Diazepam's self-taper is a real advantage, but it isn't unique to fixed dosing — we can front-load with it AND reassess by CIWA-Ar rather than committing to a rigid schedule for the full course.

Hospitalist Final

Fair — that's not actually a disagreement about the drug, just the schedule around it. Diazepam front-loaded for the first two doses given the seizure, then symptom-triggered reassessment from there. That gets him both the safety margin and the shorter course.

Regimen selected
Diazepam (front-load, then symptom-triggered)
Long-Acting Benzodiazepine
Self-tapering pharmacokinetics fit his normal liver function and his already-demonstrated seizure risk this admission.
Magnesium Repletion
Electrolyte · IV, this admission
Corrects a real, if mild, contributing factor to seizure threshold.
Where this was left

Agreed: diazepam front-loaded for the first two doses, then CIWA-Ar-triggered dosing from there, with a realistic discharge target inside his ten-day window communicated to him directly.

The pivot · Case B shares alcohol withdrawal — not a normal liver
Case B

M.V.'s three adult children drove in from out of state within a day of each other once his eldest called them: his skin had turned visibly yellow over the past two weeks, and he'd stopped answering his phone reliably, which was unlike him even at his worst. He is sixty-one, with known alcohol-associated cirrhosis diagnosed four years ago, currently Child-Pugh class B, with a history of one prior episode of mild ascites now controlled on spironolactone — no prior hepatic encephalopathy, no variceal bleed until now, if that is in fact what this turns out to be. He continued drinking steadily despite the diagnosis, roughly eight to ten drinks daily, until three days before this admission, when he ran out of money and stopped abruptly, not by choice so much as circumstance.

He arrived tremulous, tachycardic, and diaphoretic, with early disorientation to date that his children say is new — not present when they last saw him drinking regularly two months ago, and jarring enough that his eldest daughter asked twice whether he recognized her. On exam he has visible scleral icterus, a mildly distended abdomen with shifting dullness consistent with his known ascites, and a faint but present asterixis on wrist extension that the admitting resident wasn't fully confident about on a first attempt and asked a second physician to confirm. His labs show total bilirubin 3.8, albumin 2.9, INR 1.6, platelets 88, and ammonia mildly elevated at 68, with no leukocytosis or fever to suggest an obvious infectious precipitant so far, though a diagnostic paracentesis and blood cultures are both pending. He has been through withdrawal before, informally, in the stretches between relapses over the past four years, but never with jaundice this pronounced or a family in the room watching him struggle to finish a sentence.

His children keep asking the same question, understandably, in slightly different words each time they cycle through the room: is the confusion withdrawal, early hepatic encephalopathy, or both at once? His eldest has started keeping a written log of what he says and when, on her own, without being asked, because she isn't sure anyone else is tracking it closely enough. Whichever it is, it changes not just what's safe to give him, but how much of it, and how carefully anyone can watch for the difference in a man whose liver no longer clears things the way it used to — a fact none of them had to reckon with quite this directly before this week.

Patient B · M.V. Comparative Case
History
Alcohol-associated cirrhosis, Child-Pugh B × 4 years; continued drinking until 3 days ago
Liver function
T. bili 3.8, albumin 2.9, INR 1.6
Ammonia
68 µmol/L, mildly elevated
Mental status
New disorientation to date, onset since abrupt cessation
CIWA-Ar on arrival
21 (tremor, tachycardia, diaphoresis, disorientation)
What makes M.V. categorically harder
Same withdrawal syndrome as J.K., but a liver that can no longer safely clear a long-acting benzodiazepine's active metabolites — and a new disorientation that could be withdrawal, encephalopathy, or both, which changes not just which drug is safe but how much of it is safe to give at all.

Case B — a liver that can't safely clear the usual choice

Clinical Pharmacologist Opening

Switch him to lorazepam. Diazepam clears through hepatic oxidation into active metabolites with half-lives that can run to days even in healthy livers; in Child-Pugh B cirrhosis, that clearance is impaired and those metabolites accumulate further, which is exactly the mechanism behind benzodiazepine-precipitated oversedation and, in the worst cases, respiratory depression in cirrhotic patients. Lorazepam, oxazepam, and temazepam clear by direct glucuronidation — largely spared in cirrhosis — and don't carry that accumulation risk.

Hepatologist Response

I agree lorazepam is the right agent regardless of what's driving his mental status. But I want to name the thing that changes if his disorientation is hepatic encephalopathy rather than withdrawal alone: benzodiazepines can precipitate or worsen encephalopathy independent of which specific one we choose, and his ammonia is elevated with a new mental status change relative to his baseline two months ago. I'd want lactulose started and an infection/bleed workup running in parallel, not sequentially after we finish treating withdrawal.

Choosing the right drug class solves the accumulation problem, but it doesn't answer whether his confusion is actually withdrawal at all — and if it's mostly encephalopathy, more benzodiazepine of any kind could make it worse, not better.

Hospitalist Final

Then we don't have to choose which explanation is right before acting on both. Lorazepam, dosed conservatively and reassessed on a tighter interval than a standard CIWA protocol given the real ambiguity in his mental status, alongside lactulose and an active search for a precipitant. If his ammonia and mental status improve faster than his CIWA score, that tells us something about which process was driving more of the picture.

Regimen selected
Lorazepam (conservative dosing, tight reassessment)
Short-Acting Benzodiazepine · Phase 2 (Glucuronidated) Metabolism
Avoids the active-metabolite accumulation diazepam would risk in Child-Pugh B cirrhosis.
Lactulose
Non-Absorbable Disaccharide · Titrated to 2–3 soft stools/day
Started concurrently rather than after withdrawal is resolved, given his elevated ammonia and new disorientation.
Diazepam — Ruled Out
Long-Acting Benzodiazepine
Active-metabolite accumulation in Child-Pugh B disease makes it the wrong agent here, unlike in Case A.
Where this was left

Agreed: lorazepam at conservative, closely reassessed doses, lactulose started immediately, and an active infection/GI-bleed workup running in parallel rather than deferred.

Not agreed: how much of his disorientation to attribute to withdrawal versus encephalopathy going forward, and how that should shape the pace of any further sedative dosing if his CIWA score stays elevated after his ammonia normalizes. The hepatologist wants any further benzodiazepine dosing justified specifically against his mental status, not just his CIWA number, once lactulose is underway; the hospitalist is treating the CIWA score as still clinically meaningful either way. His children were told plainly that this distinction may not resolve quickly.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →